Manfidokimab Biosimilar – Anti-IL-4 receptor subunit alpha mAb – Research Grade

Description of Manfidokimab Biosimilar - Anti-IL-4 receptor subunit alpha mAb - Research Grade

Introduction

Manfidokimab Biosimilar, also known as Anti-IL-4 receptor subunit alpha mAb, is a research grade antibody that targets the IL-4 receptor subunit alpha (IL-4Rα). This antibody has shown promising results in preclinical studies and is currently being evaluated for its potential as a therapeutic agent in various diseases.

Structure of Manfidokimab Biosimilar

Manfidokimab Biosimilar is a monoclonal antibody (mAb) that is designed to specifically bind to the IL-4Rα. It is an IgG1 antibody, which means it belongs to the immunoglobulin G subclass 1. This subclass is known for its ability to activate the complement system and recruit immune cells to the site of action. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains.

The heavy chains of Manfidokimab Biosimilar are made up of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH). The light chains, on the other hand, consist of one constant domain (CL) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to the target IL-4Rα.

Mechanism of Action

The IL-4Rα is a cell surface receptor that is expressed on a variety of immune cells, including T cells, B cells, and macrophages. It is involved in the regulation of immune responses and plays a crucial role in the development of allergic and autoimmune diseases.

Manfidokimab Biosimilar works by binding to the IL-4Rα on the surface of these immune cells and blocking the binding of IL-4 and IL-13, which are two important cytokines involved in allergic and autoimmune responses. This prevents the activation of downstream signaling pathways and ultimately leads to the suppression of immune responses.

Applications of Manfidokimab Biosimilar

Manfidokimab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases, including asthma, atopic dermatitis, and rheumatoid arthritis. These diseases are characterized by an overactive immune response, and targeting the IL-4Rα with Manfidokimab Biosimilar has shown to be effective in reducing inflammation and symptoms associated with these diseases.

In addition, Manfidokimab Biosimilar has also shown potential in the treatment of certain types of cancer. IL-4Rα is overexpressed in some cancer cells, and targeting this receptor with Manfidokimab Biosimilar can inhibit tumor growth and promote cancer cell death.

Research Grade Antibody

Manfidokimab Biosimilar is currently being developed as a research grade antibody, which means it is intended for use in laboratory research and not for clinical use. This allows for further studies to be conducted to determine the safety and efficacy of the antibody before it can be used as a therapeutic agent in humans.

As a research grade antibody, Manfidokimab Biosimilar is produced in small quantities and undergoes rigorous quality control to ensure its purity and specificity. It is also available in different formulations, such as lyophilized powder and liquid, to suit different research needs.

Conclusion

In summary, Manfidokimab Biosimilar is a promising research grade antibody that targets the IL-4 receptor subunit alpha. Its unique mechanism of action and potential applications in various diseases make it a valuable tool for further research and development. With ongoing studies, Manfidokimab Biosimilar has the potential to become a novel therapeutic agent for the treatment of allergic, autoimmune, and cancerous conditions.